Race for the cure.

Both Merck and Pfizer have announced clinical trial successes of oral COVID-19 antivirals that reportedly reduce hospitalizations and death by roughly 50% and 90%, respectively, with both waiting on anticipated expedited FDA approvals. | New York Times 2021